Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
About the study
This is a Phase 2, open-label study to evaluate PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected adult subjects with metastatic NSCLC who are PD-1/PD-L1 inhibitor naïve and have progressed on a platinum based chemotherapy regimen.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Able and willing to participate and comply with all study requirements
- Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) with evaluable or measurable disease according to RECIST v1.1 with at least 1 measurable lesion
- Confirmed tumor RNA signature score
- Experienced progression of locally advanced or metastatic NSCLC after 1 prior systemic antineoplastic platinum-containing regimen (adjuvant therapy will count as a regimen if administered within 1 year before the relapse)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Predicted life expectancy of ≥ 3 months
- Adequate organ function
- WOCBP must agree to use highly effective birth control
EXCLUSION CRITERIA
Exclusion Criteria:
- Concurrent anticancer treatment or subject is expected to require any other form of antineoplastic therapy while on study, either approved or investigational.
- Current or past participation in a study of an investigational agent or using an investigational device in the metastatic setting
- Chemotherapy < 28 days prior to planned C1D1
- Prior immunotherapy including, but not limited to PD-1 or PD-L1 inhibitor mAb at any time, including JTX-4014; therapy with any mAb that specifically binds to ICOS, including vopratelimab; or chimeric antigen receptor T cell therapy
Use of anticancer therapies listed below in the metastatic setting (allowed as prior treatment for localized disease):
- Biologic therapy
- Targeted small molecule therapy
- Organ transplantation, including allogeneic or autologous stem cell transplantation
- Positive test for any of the following epidermal growth factor receptor gene mutations in blood or tumor: Exon 18 G719A; Exon 18 G719C; Exon 18 G719S; Exon 19 Del; Exon 20 S768I; Exon 20 T790M; Exon 20 Ins; Exon 21 L858R; Exon 21 L861Q
- Prior whole brain radiation
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
NSCLC
Age (in years)
18+
Phase
Phase 2
Participants needed
69
Est. Completion Date
May 31, 2024
Treatment type
Interventional
Sponsor
Jounce Therapeutics, Inc.
ClinicalTrials.gov identifier
NCT04549025
Study number
JTX-4014-202
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?